Antiviral Discovery for Highly Pathogenic Emerging Viruses
Chapter 10: Repurposing Approved Drugs to Block Highly Pathogenic Emerging Viruses
-
Published:26 Nov 2021
-
Special Collection: 2021 ebook collection
B. Mercorelli, A. Loregian, 2021. "Repurposing Approved Drugs to Block Highly Pathogenic Emerging Viruses", Antiviral Discovery for Highly Pathogenic Emerging Viruses, César Muñoz-Fontela, Rafael Delgado
Download citation file:
With the exception of influenza viruses, all the other highly pathogenic viruses considered in this book lack a specific licensed antiviral drug treatment. Despite the efforts to identify new targets and strategies, we are still unprepared in counteracting both existing and future viral pathogens that threaten worldwide public health due to their pandemic potential and great pathogenicity, which is associated with high mortality rates. The current SARS-CoV-2 pandemic has taught us how unprepared we are when a novel pathogen is introduced in the human population and how it is important to invest and to focus scientific efforts on the development of new, effective, specific drugs and therapeutic strategies against current and future emerging viral pathogens.